Structure of the Ubiquitin Hydrolase UCH-L3 Complexed with a Suicide Substrate

Shahram Misaghi, Paul J. Galardy, Wim J. N. Meester, Huib Ovaa, Hidde L. Ploegh, Rachelle Gaudet

Journal of Biological Chemistry · 2004 · 192 citations · 22 references

DOIFull text

Open access

Concepts

Abstract

Ubiquitin C-terminal hydrolases (UCHs) comprise a family of small ubiquitin-specific proteases of uncertain function. Although no cellular substrates have been identified for UCHs, their highly tissue-specific expression patterns and the association of UCH-L1 mutations with human disease strongly suggest a critical role. The structure of the yeast UCH Yuh1-ubiquitin aldehyde complex identified an active site crossover loop predicted to limit the size of suitable substrates. We report the 1.45 Å resolution crystal structure of human UCH-L3 in complex with the inhibitor ubiquitin vinylmethylester, an inhibitor that forms a covalent adduct with the active site cysteine of ubiquitin-specific proteases. This structure confirms the predicted mechanism of the inhibitor and allows the direct comparison of a UCH family enzyme in the free and ligand-bound state. We also show the efficient hydrolysis by human UCH-L3 of a 13-residue peptide in isopeptide linkage with ubiquitin, consistent with considerable flexibility in UCH substrate size. We propose a model for the catalytic cycle of UCH family members which accounts for the hydrolysis of larger ubiquitin conjugates. Ubiquitin C-terminal hydrolases (UCHs) comprise a family of small ubiquitin-specific proteases of uncertain function. Although no cellular substrates have been identified for UCHs, their highly tissue-specific expression patterns and the association of UCH-L1 mutations with human disease strongly suggest a critical role. The structure of the yeast UCH Yuh1-ubiquitin aldehyde complex identified an active site crossover loop predicted to limit the size of suitable substrates. We report the 1.45 Å resolution crystal structure of human UCH-L3 in complex with the inhibitor ubiquitin vinylmethylester, an inhibitor that forms a covalent adduct with the active site cysteine of ubiquitin-specific proteases. This structure confirms the predicted mechanism of the inhibitor and allows the direct comparison of a UCH family enzyme in the free and ligand-bound state. We also show the efficient hydrolysis by human UCH-L3 of a 13-residue peptide in isopeptide linkage with ubiquitin, consistent with considerable flexibility in UCH substrate size. We propose a model for the catalytic cycle of UCH family members which accounts for the hydrolysis of larger ubiquitin conjugates. A wide variety of cellular biochemical pathways are regulated by the post-translational addition of ubiquitin (Ub) 1The abbreviations used are: Ub, ubiquitin; BP-Ub, branched peptide HA-ubiquitin; DTT, dithiothreitol; DUB, deubiquitinating enzyme; E1, ubiquitin-activating enzyme; E2, ubiquitin carrier protein; HA, hemagglutinin; HAUb, hemagglutinin-tagged ubiquitin; MOPS, 4-morpholinepropanesulfonic acid; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)-ethyl]glycine; Ubal, ubiquitin aldehyde; Ubp, ubiquitin processing protease; UbVME, ubiquitin vinylmethylester; UCH, ubiquitin C-terminal hydrolase; USP, ubiquitin specific protease. to protein substrates (1Glickman M.H. Ciechanover A. Physiol. Rev. 2002; 82: 373-428Crossref PubMed Scopus (3380) Google Scholar, 2Hicke L. Nat. Rev. Mol. Cell. Biol. 2001; 2: 195-201Crossref PubMed Scopus (998) Google Scholar). Although the enzymatic process of ubiquitin ligation has been studied extensively, that of ubiquitin deconjugation is less well understood. A group of enzymes collectively termed deubiquitinating enzymes (DUBs) catalyzes the hydrolysis of the isopeptide linkage that joins the C-terminal glycine of ubiquitin and a lysine side chain on the target polypeptide. The DUB family consists of four structurally distinct subfamilies: the ubiquitin C-terminal hydrolases (UCHs), ubiquitin-processing proteases (Ubps, USPs), OTU domain-containing enzymes (otubains) and the Jab/MPN domain-associated metalloisopeptidase domain-containing metalloproteases (3Wilkinson K.D. FASEB J. 1997; 11: 1245-1256Crossref PubMed Scopus (511) Google Scholar, 4Wing S.S. Int. J. Biochem. Cell Biol. 2003; 35: 590-605Crossref PubMed Scopus (163) Google Scholar). The first three enzyme classes all possess the sequence signature of cysteine proteases: a conserved catalytic triad of cysteine, histidine, and aspartic acid residues. Sequence analysis of the human genome predicts at least 100 DUBs, which begs the question of their physiological roles. Although restricted substrate specificity is predicted to underlie the requirement for such a large enzyme family, little is known about substrate specificity determinants. The recently published structures for the Ubp family member USP7 (HAUSP) in the unliganded and liganded state (5Hu M. Li P. Li M. Li W. Yao T. Wu J.W. Gu W. Cohen R.E. Shi Y. Cell. 2002; 111: 1041-1054Abstract Full Text Full Text PDF PubMed Scopus (493) Google Scholar) affords a unique opportunity to examine specificity determinants for this enzyme. Although the HAUSP catalytic residues are misaligned in the unliganded state, the catalytic core undergoes a dramatic conformational change when in a complex with the inhibitor ubiquitin aldehyde (Ubal), resulting in alignment of the catalytic residues with the C terminus of Ub. The open configuration of the HAUSP active site explains the ability of this class of enzyme to accommodate large ubiquitin conjugates as substrates (e.g. p53). In contrast, the UCH enzymes have an apparent preference for small C-terminal leaving groups, as typified by ubiquitin ethyl ester (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar). The crystal structure of the yeast enzyme Yuh1 in a complex with Ubal provided some insights into the substrate specificity of UCHs (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar). A 20-residue loop was observed to cover the active site cleft and is thus inferred to impose a limit on the size of the Ub-conjugated substrate that Yuh1 can accommodate. However, this model does not explain the apparent ability of some UCHs to hydrolyze much larger substrates (8Roff M. Thompson J. Rodriguez M.S. Jacque J.M. Baleux F. Arenzana-Seisdedos F. Hay R.T. J. Biol. Chem. 1996; 271: 7844-7850Abstract Full Text Full Text PDF PubMed Scopus (206) Google Scholar, 9Baek S.H. Yoo Y.J. Tanaka K. Chung C.H. Biochem. Biophys. Res. Commun. 1999; 264: 235-240Crossref PubMed Scopus (6) Google Scholar, 10Layfield R. Franklin K. Landon M. Walker G. Wang P. Ramage R. Brown A. Love S. Urquhart K. Muir T. Baker R. Mayer R.J. Anal. Biochem. 1999; 274: 40-49Crossref PubMed Scopus (31) Google Scholar), suggesting potential alternate conformations. This active site crossover loop could not be resolved in the crystal structure for unliganded human UCH-L3 (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar), suggesting that this loop may have significant flexibility in the unliganded state. Although several ligand-induced conformational changes were inferred upon comparison of the structure for UCH-L3 with that of Yuh1·Ubal, the limited sequence identity between UCH-L3 and Yuh1 (30%) complicates a direct comparison. To explain the properties and substrate preference of UCHs we describe the 1.45 Å crystal structure of human UCH-L3 in a complex with the mechanism-based inhibitor ubiquitin vinylmethylester (UbVME). This structure allows the direct comparison of conformational changes that occur between the unliganded (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar) and Ub-bound states of UCH-L3. We also report the synthesis of a branched peptide substrate that consists of an N-terminally biotinylated 13-residue peptide, with its sequence centered on ubiquitin lysine 48, in isopeptide linkage with HA-tagged Ub (HAUb). Although the configuration of the active site crossover loop observed in our structure precludes the accommodation of such a large isopeptide-linked substrate, we show that UCH-L3 can nonetheless hydrolyze the isopeptide bond in this branched peptide. Taking into consideration both the observed structure and substrate specificity, we propose a model for UCH-mediated Ub conjugate hydrolysis. Protein Expression and Purification—UCH-L3 in pRSET vector was obtained from Dr. Keith Wilkinson. UCH-L3 was expressed in Escherichia coli and purified as described previously (12Larsen C.N. Price Wilkinson K.D. Biochemistry. 1996; 35: PubMed Scopus Google Scholar). Expression and of ubiquitin synthesis and ligation of the glycine to ubiquitin, and of the complex were as described previously A. T. Wilkinson K.D. Chem. Biol. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). To the the of the was to by the addition of UCH-L3 DTT, and was that the was of at of and of UCH-L3 at The was for at and the of the which in an in of was by UCH-L3 and were on a a from to in A DTT, and the complex were DTT, and to and of Ub of was with of of and of A DTT, and of a was to the and the was for at to the branched peptide The of this were by with the the of a of the and To the of DTT, and of UCH-L3 were to the of and were at were at and by the addition of and resolved on a peptide The were to a and biotinylated were with The was and with to the of the and were by at from of protein in DTT, and of and were in a and and in were to 1.45 Å with an at at the of The to group with a with were are in and of is the of the of a from the of its and in in is the structure is as for for of that were from the of of bond bond is the of the of a from the of its and is the structure is as for for of that were from the in a and structure was by in P. J. M. R.J. T. Biol. 1998; PubMed Scopus Google Scholar) the human UCH-L3 (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar) and human ubiquitin S. Wilkinson K.D. Cook W.J. J. Biol. Chem. Full Text PDF PubMed Google Scholar) structures as and identified for both UCH-L3 and ubiquitin, to the in the was with A. PubMed Scopus Google Scholar) was used for model The model residues and for the first and of residues of ubiquitin and the glycine for both of the and and of UCH-L3 were The side of of of and of were not analysis used and and were with M. 1997; PubMed Scopus Google Scholar). and UCH-L3 was expressed in and in with at to the complex UCH-L3 was from the complex by The distinct to the liganded and free UCH-L3 A of consistent with covalent of to is when the are by has been that the physiological of UCHs may be the of active ubiquitin from small C-terminal such as that occur cellular (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar, S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar, J. Biol. Chem. Full Text PDF PubMed Google Scholar). However, a potential of UCH-L3 has been to for of a to Ub in isopeptide linkage to a substrate free UCH-L3 does hydrolyze a lysine in isopeptide linkage to the C-terminal glycine of ubiquitin (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar, 10Layfield R. Franklin K. Landon M. Walker G. Wang P. Ramage R. Brown A. Love S. Urquhart K. Muir T. Baker R. Mayer R.J. Anal. Biochem. 1999; 274: 40-49Crossref PubMed Scopus (31) Google Scholar) to a ubiquitin in which the C terminus of ubiquitin is an isopeptide bond to lysine of a ubiquitin (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar). To the ability of UCH-L3 to isopeptide-linked we an N-terminally acid peptide to Ub residues with a lysine at of Ub. In addition to an for this peptide, the group that the lysine the free in this peptide. The C-terminal glycine of was to the group of the peptide purified and ubiquitin to a branched complex The adduct both an (Ub) and a We the ability of UCH-L3 to hydrolyze the isopeptide bond of the The substrate was in the of and were at UCH-L3 by with as a The were resolved by to a and with to the of biotinylated branched peptide. that UCH-L3 the isopeptide as by the of the of as Although the of in small an of substrate and catalytic we a of at least we substrate in we that is a suitable substrate for UCH-L3. for and of on a to are complex was and its structure was to 1.45 Å resolution and The model all ubiquitin and UCH-L3 residues for the UCH-L3 first for which no was The UCH-L3 structure consists of a by an and loop that were in the unliganded UCH-L3 structure (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar). We to this as the previously is also that residues and a conserved on the to the of the residues are conserved all human and not which an in this are are with a of Å on for UCH-L3 and Å for However, by the UCH-L3 structures we a of between the This a that residues and of ubiquitin, leaving the C-terminal Ub residues and loop residues Although this of ubiquitin is a resulting from crystal that the C terminus and the first loop of the ubiquitin comprise the with UCH-L3 In contrast, the of and of with and at the of which are in are determinants of specificity can be by the crystal the the of with C-terminal are specific of DUBs, UCH-L3 A. T. Wilkinson K.D. Chem. Biol. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, A. R. Wilkinson K.D. EMBO J. 2001; PubMed Scopus Google Scholar). the specificity of a of has not been for of an active peptide. has been that of by ubiquitin may occur covalent of the active site cysteine of the active site The 1.45 Å crystal structure of allows the of the by this UCH-L3 with in a addition to a of the in the UCH-L3 active site of a covalent bond between the side chain of cysteine and the group of the inhibitor as The of the bond to the of the ubiquitin glycine which is the site of ubiquitin from substrates of The to the of inhibitor alternate for this free of the group between UCH-L3 and are residues in the complex a of residues an in the of ubiquitin in the active site of UCH-L3. The C terminus of ubiquitin is in the active site cleft of UCH-L3. of ubiquitin forms an and with UCH-L3 residues. with several at the C terminus of This of may the previously active site crossover loop the C terminus of an conserved all UCH family of forms a with of UCH family conserved residues with the C-terminal residues of ubiquitin and and the and the first loop of ubiquitin between and the loop between and of resulting in an of and of ubiquitin with and residues of UCH-L3. in The structure of unliganded human UCH-L3 has been previously (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar). The resolution structure of the complex allows the of the conformational changes observed when UCH-L3 with Ub. our structure of UCH-L3 in complex with is to that of free UCH-L3 Å in both Å when of apparent conformational change are from unliganded UCH-L3 and UCH-L3 significant conformational in to the active site The change is the of a previously loop of UCH-L3 into a by an loop that the active site of the enzyme. from an in the unliganded structure to the first of the in the The residues of UCH-L3 also a conformational an that the active site cleft for of the C terminus of ubiquitin and with the This forms with the C terminus of Ub. We also an Å of and its loop as well as the loop in UCH-L3 to accommodate of the of the all of changes are to the active site of UCH-L3 to its ubiquitin conjugate substrates. The of Yuh1 have in the complex (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar). on the of Yuh1 with UCH-L3 was that UCH-L3 a is and a conserved substrate mechanism the UCH family the of the crossover loop is for UCH-L3 and the sequence between in that Although the UCHs are the DUBs, their catalytic in Ub has to be we describe a resolution crystal structure for UCH-L3 in a complex with the DUB inhibitor The of the UCH-L3 structure in the unliganded state (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar) allows a of conformational changes that occur when Ub the sequence identity between UCH-L3 and Yuh1 we a between our structure and that of Yuh1 in complex with This of that the described by (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar, S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar) and in this report may well be the UCH we a in the of Ub into the UCH-L3 active site cleft for the in the The observed to the of of between UCH-L3 and Ub. We that are of in substrate by UCH-L3. were not observed in the were not predicted on with UCH-L3 K.D. J. 1999; PubMed Scopus Google Scholar), are residues conserved UCHs thus this In contrast, the of between UCH-L3 and both the C terminus and the first loop of Ub is by the that between both with biochemical and the C terminus of Ub with the active site cleft of UCH-L3. Although the C-terminal is in of the and the critical residues and in that with UCH-L3 and Yuh1 (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar). is that UCH-L3 J. A. Cook J. T. Wilkinson K.D. G. Mol. Cell. Biol. PubMed Scopus Google Scholar, K. T. Biochem. Biophys. Res. Commun. 1998; PubMed Scopus Google Scholar). The between Ub and in their C in the to the first loop of Ub, underlie the of in UCH-L3 J. A. Cook J. T. Wilkinson K.D. G. Mol. Cell. Biol. PubMed Scopus Google Scholar). We several ligand-induced conformational changes that are in with inferred from the structure of Yuh1 in complex with Ubal (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar). to the structure described an model the of specific between UCH-L3 and Ub K.D. J. Larsen C.N. J. Mol. Biol. 1999; PubMed Scopus Google Scholar). The model of the residues between UCH-L3 and Ub is The predicted of of Ub with and of UCH-L3 were the predicted with was We the predicted of and of Ub with as well as the predicted between and the group of of Ub with residues and of UCH-L3. Although the structure of the complex is to that described for the yeast enzyme our structure of the complex allows the first direct comparison of a UCH enzyme in the free and ligand-bound state. This comparison the of the dramatic changes in which occur in the terminus of UCH-L3 to accommodate the C terminus of Ub into the active site cleft of UCH-L3. the structure from that of in that UCH-L3 an that forms at the of the active site crossover This also was observed to with the C terminus of Ub at thus the of the Ub C terminus in the active site The structure described also a of Ub, not apparent in the This that the C-terminal residues and the first loop of Ub are critical as are in the our structure that and by to Ub a class of the active site cysteine of We have Ub with a variety of that can with at least DUBs, all human UCHs, and the OTU enzymes and A. T. Wilkinson K.D. Chem. Biol. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, A. R. Wilkinson K.D. EMBO J. 2001; PubMed Scopus Google Scholar, M. S. S. Biochem. J. PubMed Scopus Google Scholar, S. A. PubMed Scopus Google Scholar). for the analysis of the UCH-L3 was to the mechanism of for this class of The we obtained that UCH-L3 by a covalent bond with the active site cysteine We with which that members of the Ubp family of the active site observed in this crystal This mechanism-based inhibitor allows to and enzyme for in A. R. Wilkinson K.D. EMBO J. 2001; PubMed Scopus Google We have this to DUB from a of human and observed tissue-specific DUB Although members of the UCH family of have been to disease states as well as in K. W. A. M. Cell. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar) the of substrates for enzymes has their apparent preference for small C-terminal leaving from Ub, UCHs have been to small of that are to the C terminus of the ubiquitin a peptide free ubiquitin (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar, J. Biol. Chem. Full Text PDF PubMed Google Scholar, Biochemistry. PubMed Scopus Google Scholar). In this ubiquitin that with ubiquitin with may substrates for UCH-L3 J. Biol. Chem. Full Text PDF PubMed Google Scholar). that UCH-L1 of free ubiquitin Wang K. S. R. Li Y. K. Y.J. M. T. Y. S. K. M. S. K. Mol. 2003; PubMed Scopus Google Scholar). The active site crossover loop in human UCH-L3 (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar) its observed in the structure (7Johnston S.C. Riddle S.M. Cohen R.E. Hill C.P. EMBO J. 1999; 18: 3877-3887Crossref PubMed Scopus (254) Google Scholar) and this may be in of a of substrates to the UCH-L3 active is that to the C terminus of ubiquitin have to be the UCH-L3 active site crossover loop the glycine of Ub is at the UCH-L3 active of C-terminal of Ub the UCH-L3 active site crossover loop be and are the size of the Ub conjugate However, is no biochemical that UCH-L3 substrates are the active site crossover in addition to our that UCH-L3 and its can process a of to the C terminus of ubiquitin which is larger and A ubiquitin of ubiquitin in with a protein has been to be a substrate for and (6Larsen C.N. Krantz B.A. Wilkinson K.D. Biochemistry. 1998; 37: 3358-3368Crossref PubMed Scopus (350) Google Scholar, 10Layfield R. Franklin K. Landon M. Walker G. Wang P. Ramage R. Brown A. Love S. Urquhart K. Muir T. Baker R. Mayer R.J. Anal. Biochem. 1999; 274: 40-49Crossref PubMed Scopus (31) Google Scholar). an adduct larger is also an in substrate for (8Roff M. Thompson J. Rodriguez M.S. Jacque J.M. Baleux F. Arenzana-Seisdedos F. Hay R.T. J. Biol. Chem. 1996; 271: 7844-7850Abstract Full Text Full Text PDF PubMed Scopus (206) Google Scholar). with and active site crossover loop identity to human can ubiquitin from a protein both in and in S.H. Yoo Y.J. Tanaka K. Chung C.H. Biochem. Biophys. Res. Commun. 1999; 264: 235-240Crossref PubMed Scopus (6) Google Scholar). on the highly conserved structures of and is that are no significant between which are between and with UCH-L3. the substrate specificity of UCH-L3 was a of sequence is on J. Biochemistry. PubMed Scopus Google Scholar). A branched peptide substrate was of the C-terminal residues of Ub in isopeptide linkage to the lysine of a 13-residue peptide. the sequence of Ub as the a peptide was in which the residues between and are Although UCH-L3 a preference for residues at substrates of sequence were The ability to model substrate branched is limited by the of a Ub as could the branched peptide the active site crossover loop in we have an N-terminally 13-residue peptide to residues of ubiquitin and the C-terminal of an to the of the of this peptide an isopeptide The resulting complex is a substrate for UCH-L3 in and the first peptide that is a substrate for UCH-L3. Ubiquitin the for the substrate specificity of UCHs, and the branched be of a substrate may be by the of a of on the residues the to which ubiquitin is The to substrate specificity is the of a 20-residue loop that the active site cleft both in Yuh1 and UCH-L3. This loop be in model that accounts for the size of substrates by in substrates the active site cleft by the by the active site crossover This model explain the ability of UCHs to hydrolyze small Ub C-terminal as the loop impose significant size on potential substrates. However, the of larger substrates by UCH enzymes with the model of substrate the crossover The of the active site crossover loop in its and open is highly that the of a branched such as BP-Ub, with such a small and large be to accommodate the alternate model for UCH hydrolysis is thus to for the observed of To accommodate larger substrates in the active site of UCHs by the active site crossover loop from the active site cleft (11Johnston S.C. Larsen C.N. Cook W.J. Wilkinson K.D. Hill C.P. EMBO J. 1997; 16: 3787-3796Crossref PubMed Scopus (214) Google Scholar). the catalytic cycle of UCH-L3 in the hydrolysis of a branched peptide substrate into ubiquitin and a free peptide that this model could also be to larger UCH-L3 UCH-L3 and a ubiquitin with the active site crossover loop from the active of the C terminus of ubiquitin into the active site the UCH-L3 to an with with the C terminus of Ub. conformational changes and the loop of the ubiquitin adduct In this the active site cleft as a on which the C terminus of ubiquitin ubiquitin and the branched peptide are on of the enzyme. the active site a on the group of the of ubiquitin, the isopeptide bond between ubiquitin and the branched peptide and a covalent with The branched peptide be from the active site the active site crossover loop to the active site cleft in the observed in our The crossover loop in this forms with ubiquitin the C terminus of The active site residues and a which the covalent bond between of UCH-L3 and of ubiquitin on the group of of The the of ubiquitin with the of the terminus of UCH-L3 to its unliganded The of this model are that the of the active site crossover loop to substrate allows its from the active site and large substrates and by sequence of the crossover loop the UCH family may a in substrate specificity specific of substrates with the and the structures of and the of the crossover loop in the covalent state the substrate A of the of active site crossover loop is to the active site residues in their active the active site crossover in the may to of all the (e.g. into the active site thus the of that may from the of larger of UCH enzymes be to the and of the UCH active site crossover loop in substrate and We Dr. for the of human UCH-L3 and the for that the

References

22